Safety of neurokinin-1 receptor antagonists

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 673-685

  Muñoz, Miguel ^a   Coveñas, Rafael ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Aprepitant; Casopitant; Clinical trial; CP 122,721; Ezlopitant; Fosaprepitant; NK 1 receptor antagonists; Safety; Side effects; Tolerability; Vofopitant

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; APREPITANT; CASOPITANT; CJ 12255; DEXAMETHASONE; DIGOXIN; DINACICLIB; DOCETAXEL; EZLOPITANT; FOSAPREPITANT; GRANISETRON; HYDRODOLASETRON; IFOSFAMIDE; IRINOTECAN; L 759274; METHYLPREDNISOLONE; MIDAZOLAM; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PACLITAXEL; PALONOSETRON; ROLAPITANT; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ALOPECIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ASTHENIA; CONSTIPATION; CORTICOSTEROID THERAPY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSTONIA; FATIGUE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HICCUP; HUMAN; INFECTION; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; REVIEW; TRANQUILIZING ACTIVITY; VOMITING;

HUMANS; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS;

EID: 84883007375     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.804059     Document Type: Review

References (86)

1. Munoz M, Covenas R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 2011;18:1820-31
2. Stahl SM. The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting. J Clin Psychiatry 2003;64:498-9
3. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-5
4. Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized, double-bind, placebo-controlled studies of the novel NK-1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:727-33
5. Kalinichev M, Bradford A, Bison S, et al. Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK-1 receptor antagonist in the rat. Epilepsia 2010;51:1543-51
6. George DT, Gilman J, Hersh J, et al. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008;319:1536-9
7. Rodr?guez D, Covenas R. Targeting opioid and neurokinin-1 receptors to treat alcoholism. Curr Med Chem 2011;18:4321-34
8. Bang R, Sass G, Kiemer AK, et al. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 2003;305:31-9
9. Yu J, Cadet JL, Angulo JA. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 2002;83:613-22
10. Castro-Obregon S, del R?o G, Chen SF, et al. A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. Cell Death Differ 2002;9:807-17
11. Bang R, Biburge M, Neuhuber WL, et al. Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage. J Pharmacol Exp Ther 2004;308:1174-80
12. Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:2535-40
13. Manak MM, Moshkoff DA, Nguyen LT, et al. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS 2010;24:2789-96
14. Munoz M, Rosso M, Covenas R, et al. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 2007;48:2775-81
15. Munoz M, Rosso M, Robles-Fr?as MJ, et al. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 2010;90:1259-69
16. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,DTrp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005;65:2738-45
17. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-8
18. Munoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad-spectrum antitumor drug. Invest New Drugs 2010;28:187-93
19. Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-bind, placebo-controlled phase 3 trial. Ann Oncol 2012;published online 31 October 2012; doi: 10.1093/annonc/mds541
20. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004;32:1287-92
21. Ruhlmann CH, Herrstedt J. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 2011;10:449-62
22. Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic. Biol Blood Marrow Transplant 2013;19:49-55
23. Olver I, Shelukar S, Thompson KC. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine 2007;2:13-18
24. Jin Y, Wu X, Guan Y, et al. Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Support Care Cancer 2012;20:1815-22
25. Herrington JD, Jaskiewicz A, Song J. Ramdomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-7
26. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6
27. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
28. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
29. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-bind, placebo controlled trials. Eur J Cancer 2005;41:1278-85
30. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012;104:1280-92
31. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69:1853-78
32. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-10
33. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11
34. Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-bind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008;27:609-15
35. de Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-8
36. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19
37. Loos WJ, de Wit WR, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12
38. Zhang D, Mita M, Shapiro GI, et al. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemother Pharmacol 2012;70:891-8
39. Bubalo JS, Cherala G, McCune JS, et al. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2012;52:586-94
40. Durand JP, Gourmel B, Mir O, et al. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007;18:808-9
41. Depre M, van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341-6
42. Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52:242-7
43. Bergman AJ, Marbury T, Fosbinder T, et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005;44:637-47
44. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011;29:1495-501
45. Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011;51:1712-20
46. Marbury TC, Jin B, Panebianco D, et al. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesth Analg 2009;109:418-25
47. Tebas P, Tuluc F, Barret JS, et al. A randomized, placebo controlled, double masked phase Ib study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One 2011;6:e24180
48. Jordan K, Jahn F, Jahn P, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 2011;46:784-9
49. Abidi MH, Tageja N, Ayash L, et al. Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial. Support care Cancer 2012;20:2363-9
50. Pielichowski W, Barzal J, Gawronski K, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 2011;43:3107-10
51. Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase II trial in patients undergoing open abdominal surgery. Br J Anaesth 2007;99:202-11
52. Egerer G, Eisenlohr K, Gronkowski M, et al. The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010;70:903-7
53. Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg 2011;112:813-18
54. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999;340:190-5
55. Longo F, Mansueto G, Lapadula V, et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 2012;66:753-7
56. Gao H, Liang Y, Zhou N, et al. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin-based chemotherapy. Intern Med J 2013;43:73-6
57. Longo F, Mansueto G, Lapadula V, et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2011;19:1159-64
58. Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer 2012;20:653-6
59. Takahashi T, Nakamura Y, Tsuya A, et al. Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 2011;68:653-9
60. Olver IN, Grimison P, Chatfield M, et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 2012;published online 30 December 2012; doi: 10.1007/s00520-012-1696-0
61. Vo TT, Nelson JJ. Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study. J Cancer Epidemiol 2012; doi: 10.1155/2012/529357
62. Navari RM, Gray SE, Kerr A. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188-95
63. Kakuta N, Tsutsumi YM, Horikawa YT, et al. Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. J Med Invest 2011;58:246-51
64. Santini D, Vicenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012;13:1020-4
65. Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010;5:e10968
66. Altorjay A, Melson T, Chinachoit T, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis. Arch Surg 2011;146:201-6
67. Bauman JW, Antal JM, Adams LM, et al. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Invest New Drugs 2012;30:662-71
68. Jonhson BM, Adams LM, Zhang K, et al. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol 2010;50:951-9
69. Singla NK, Singla SK, Chung F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW-679,769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology 2010;113:74-82
70. Roila F, Rolski J, Ramlau R, et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 2009;20:1867-73
71. Arpornwirat W, Albert I, Hansen VL, et al. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 2009;115:5807-16
72. Johnson B, Adams L, Lu E, et al. Impact of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 2009;17:1177-85
73. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009;27:5363-9
74. Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin-1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:549-58
75. Dandamudi UB, Adams LM, Johnson B, et al. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer Chemother Pharmacol 2011;67:783-90
76. Diemunsch P, Schoeffler P, Bryssine B, et al. Antiemetic activity of the NK1 receptor antagonist GR-205,171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999;82:274-6
77. Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011;21:221-9
78. Furmark T, Appel L, Michelgard A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR-205,171, citalopram, or placebo. Biol Psychiatry 2005;58:132-42
79. Reid K, Palmer JL, Wright RJ, et al. Comparison of the neurokinin-1 antagonist GR-205,171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000;50:61-4
80. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385-92
81. Michelson D, Hargreaves R, Alexander R, et al. Lack of efficacy of L-759,274, a novel neurokinin-1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2013;16:1-11
82. Gesztesi Z, Scuderi PE, White PF, et al. Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000;93:931-7
83. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-43
84. Gan TJ, Gu JG, Singla N, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg 2011;112:804-12
85. Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010;184:616-22
86. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-6